Intra-Day Reversal In Amarin

Shares of biotech firm Amarin, Inc. AMRN have been on fire over the last few months, as the company has reported positive Phase III trial data for its cardiovascular drug AMR101. The shares are lower on Wednesday, however, after spending a good part of the day trading higher. AMRN is currently down 1.69% to $18.59 after trading as high as $19.38 earlier in the day.